[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-morbidity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-morbidity":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,66,93,127,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100554765","a-hospital-based-registry-of-preventive-cardiology-clinics-100554765",false,"NCT06503341","A Hospital-Based Registry of Preventive Cardiology Clinics","Assessment and Control of Modifiable Risk Factors for Primary and Secondary Prevention","PREVENT-CARD","Inclusion Criteria:\n\n* All individuals attending the preventive cardiology clinics.\n\nExclusion Criteria:\n\n* • Individuals who refused to give consent.",true,"ALL","18 Years","90 Years",{"count":22,"type":23},10000,"ESTIMATED","10 Years","OBSERVATIONAL","More research is needed to articulate the most effective ways to use these tools as screening tests in cardiovascular risk assessments and how they ultimately affect CVD mortality and morbidity outcomes. Clinicians are encouraged to continue sharing decision-making with patients to combine their unique cardiovascular risk factors and develop a comprehensive, effective treatment plan.",[28,29,30],"Cardiovascular Morbidity","Cardiovascular Risk Assesment","Primary Prevention CVD","RECRUITING","2026-04-09",{"date":34,"type":35},"2026-04-13","ACTUAL",{"date":37,"type":35},"2021-06-17",{"date":39,"type":23},"2041-06-01",{"name":41,"class":42},"National Institute of Cardiovascular Diseases, Pakistan","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":43},"100619066","diagnosis-of-transient-ischemic-attacks-in-the-emergency-department-100619066","NCT07339787","Diagnosis of Transient Ischemic Attacks in the Emergency Department","DAITSU","Inclusion Criteria:\n\n* Adult (≥18 years old)\n* Having consulted the emergency department or been diagnosed with TIA during the period from January 1, 2024, to December 12, 2024 (records will be compiled via coding at the East Rescue regional emergency observatory)\n* TIA will be defined as a sudden, transient neurological deficit that had disappeared by the time of arrival at the emergency department\n\nExclusion Criteria:\n\n\\- Subjects with a suspected diagnosis of TIA, i.e., with a sudden, transient neurological deficit that had disappeared by the time of arrival at the emergency department.",{"count":52,"type":23},300,"Patients presenting a Transient Ischemic Attack (TIA) and admitted to the Emergency Department should be referred to a neurovascular specialist. In recent years, several hospitals have established TIA clinics. These units are day hospitals where all the necessary examinations are performed. Access to this expertise has proven beneficial in reducing cardiovascular morbidity and mortality, particularly the risk of early recurrence. Unfortunately, this access is limited by issues of medical demographics and unequal access to the healthcare system. In practice, this ideal care is not always possible. A portion of the TIA population is at low risk, and diagnostic and therapeutic interventions are limited, not always requiring neurovascular expertise.\n\nThe hypothesis of this research is that the management of a patient who has suffered a TIA (additional examinations, treatment, referral) is not linked to their cardiovascular risk and that the performance of additional examinations and therapies is incomplete.",[55,28],"Transient Ischemic Attack",[55,28],"2026-01-05",{"date":59,"type":35},"2026-01-14",{"date":61,"type":35},"2025-02-06",{"date":63,"type":23},"2027-01-06",{"name":65,"class":42},"University Hospital, Strasbourg, France",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":73,"minAge":19,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100472513","impact-of-metabolic-health-patterns-and-breast-cancer-over-time-in-women-100472513","NCT05432856","Impact of Metabolic Health Patterns And Breast Cancer Over Time in Women","IMPACT-Women","Inclusion Criteria:\n\n* Female biological sex at birth\n* \\>18 years\n* Diagnosis of stage I, II, or III breast cancer\n* starting neoadjuvant or adjuvant intravenous chemotherapy\n* ECOG \\\u003C3;\n* Oncologist approval to participate;\n* English speaking (all study materials and study staff will be in English)\n* Willing and able to adhere to study intervention\n\nExclusion Criteria:\n\n* Individuals who do not have access to a smart phone with Bluetooth capability (required for Fitbit and for responding to intervention text messages) or at least a shared cell phone with someone in the same household (i.e., some couples may share a phone).\n* Type 1 or type 2 diabetes who require exogenous insulin (due to the potential need to adjust insulin dosing with TRE) or with hemoglobin A1c \\>10%\n* Research MRI contraindications (e.g., pacemaker, magnetic implants, pregnancy)\n* Uncontrolled thyroid disorder\n* Self-reported eating disorder history\n* Body mass index \\\u003C18.5 kg\u002Fm2 or clinical signs of cachexia (discretion of treating oncologist)\n* ≥5% body weight loss within last 6 months\n* Those who are currently working night\u002Frotating shifts, eating within ≤10-hour window or consistently eating less than 3 meals\u002Fday in the past 3 months.\n* patients who meet the criteria for medical clearance prior to exercise using the Physical Activity Readiness Questionnaire+ and are not cleared by their treating oncologist or family physician to perform maximal exercise testing.","FEMALE",{"count":75,"type":23},65,"INTERVENTIONAL",[78],"NA","Background \\& Rationale:\n\nBreast cancer (BC) is the most commonly diagnosed malignancy in women worldwide (2.1 million diagnoses in 2018, 25% of new cancer cases). In Canada, early stage BC mortality rates have decreased by 48% over the past 30 years as a result of advances in prevention, detection, and treatment. However, competing risks for mortality from non-cancer causes have emerged, where cardiovascular disease (CVD) is now a leading cause of death for BC survivors. The direct toxic effects of BC treatment on the heart (cardiotoxicity) are well characterized by the investigators and many others, as a contributor to elevated cardiovascular risk. However, BC treatment and the associated lifestyle changes (i.e. physical inactivity, poor diet quality, stress) are increasingly recognized to also strongly affect metabolism negatively manifesting as insulin resistance, dyslipidemia and adipose tissue (fat) accumulation. These adverse metabolic changes are strongly linked to CVD risk and represent a currently underappreciated contributor to the elevated CVD risk among BC survivors. Preliminary data and recent publications demonstrate that regional fat accumulation occurs during BC treatment and that the fat burden in key locations is associated with poor cardiorespiratory health. A trigger of these adverse metabolic and inflammatory effects is excess fat specifically within ectopic fat (viscera, intermuscular, or hepatic) regions. In 2019, a member of the study team found that the volume of visceral and intermuscular but not subcutaneous fat at BC diagnosis were linearly associated with CVD events within 6 years, even among those with normal BMI and after adjustment for pre-existing CVD risk factors and for BC treatment type. Using MRI, investigators found that \\~1 year after chemotherapy, BC survivors had significantly larger depots of visceral fat (49% larger) and thigh intermuscular fat (41% larger) compared to age and sex-matched controls, despite similar BMI and subcutaneous fat volumes in the two groups. Investigators also showed that the fat fraction within the thigh muscle and visceral fat volumes independently explained \\~50% of the variation in cardiorespiratory fitness (measured by peak VO2). In particular, peak VO2 is one of the most powerful predictors of all-cause and CVD mortality and health care costs, and is the most consistently reported negative sequelae after treatment for BC. Unfortunately, there are no known therapies to recover long-term myocardial damage (i.e. cell death, fibrosis) from cancer therapies. There are several reasons to target fat as a therapeutic target in BC patients: 1) The study team have compelling preliminary data showing accelerated formation of ectopic fat during BC treatment. 2) Investigator's recent data showed that high fat content in key fat pools was associated with reduced peak VO2. 3) The burden of fat and the associated metabolic abnormalities are dynamic and malleable, and thus highly treatable.\n\nResearch Question \\& Objectives:\n\nThe primary purpose of this study is to evaluate the effect of a behavioural intervention involving supported time-restricted eating (TRE), diet quality improvements, and reduced sedentary time versus usual cancer and nutrition care in BC patients receiving chemotherapy treatment on ectopic fat, cardiometabolic profile, and chemotherapy outcomes. The investigators hypothesize that the intervention will attenuate the growth of ectopic fat during chemotherapy and reduce chemotherapy symptoms.",[81,28,82],"Cardiovascular Diseases","Metabolic Disease","2025-08-20",{"date":85,"type":35},"2025-08-27",{"date":87,"type":35},"2024-03-13",{"date":89,"type":23},"2027-06",{"name":91,"class":42},"University of Alberta",2,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":100,"minAge":19,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":76,"phases":103,"briefSummary":105,"conditions":106,"keywords":113,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":43},"100500889","early-phase-1-akkermansia-muciniphilia-and-metabolic-side-effects-of-adt-100500889","NCT05802121","Akkermansia Muciniphilia and Metabolic Side Effects of ADT","The Role of Akkermansia Muciniphilia in Combating the Metabolic Effects of Androgen Deprivation Therapy in Men With Metastatic Prostate Cancer","For inclusion in this study, patients must fulfill all of the following criteria:\n\n1. Men ≥18 years of age with histologically-proven metastatic castration-sensitive prostate adenocarcinoma planned to receive ADT (TNM stage Tany, Nany, M1) (see Appendix I).\n2. Must have baseline imaging with 1) CT of the abdomen, and pelvis and bone scan or 2) PSMA PET scan\n\nPatients fulfilling any of the following criteria are NOT eligible for participation in this study:\n\n1. Age less than 18\n2. Primary neuroendocrine prostate cancer\n3. Treatment with ADT within the year leading up to enrolment\n4. Planned or concurrent use of chromium supplementation for the study duration\n5. Planned or concurrent use of apple cider vinegar supplementation for the study duration\n6. Unable to provide informed consent or unable to understand or read the English language (unless accompanied by an interpreter)\n7. Inadequate liver function (\\>2x upper limit of normal)\n8. Any other condition, chronic disease, or lifestyle factor, that, in the opinion of the Qualified Investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant\n9. Use of antibiotics that cannot be discontinued for a washout period and remain off them for the duration of the trial","MALE",{"count":102,"type":23},30,[104],"EARLY_PHASE1","The overriding objectives of this study are:\n\n1. Primary outcomes:\n\n   1. To confirm that administration of oral acetate increases the proportion of A. muciniphilia in the stool samples of patients with metastatic, castration-sensitive prostate cancer compared to a standard of care arm.\n   2. To confirm tolerability and assess for side effects of oral acetate supplementation.\n2. Secondary outcomes:\n\n   1. To determine if increased counts of A. muciniphilia correlate with improved metabolic parameters and improved bone health.",[107,108,109,28,110,111,112],"Prostate Cancer","Metabolic Syndrome","Obesity","Bone Diseases","Hyperlipidemias","Diabetes",[114,115,116,117,118,119],"prostate cancer","metabolic syndrome","androgen deprivation therapy","microbiome","Akkermansias muciniphilia","cardiovascular disease","2025-08-15",{"date":83,"type":35},{"date":123,"type":35},"2025-07-02",{"date":89,"type":23},{"name":126,"class":42},"Western University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":43},"100532069","arterial-stiffening-as-a-predictor-for-diastolic-cardiac-dysfunction-and-hfpef-100532069","NCT06208007","Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF","ARTSPREDICTION","Inclusion Criteria:\n\nOne or more of the following criteria:\n\n* Age \\> 60 years\n* Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs)\n* Diabetes mellitus Type I or II\n* Atrial fibrillation\n* Chronic kidney disease (GFR \\\u003C 60 ml\u002Fmin\u002F1,73 m2 or urine albumin ≥ 30mg\u002F24h or ACR ≥ 30 mg\u002Fg)\n* BMI ≥ 30 kg\u002Fm2\n* NYHA ≥ II\n* E\u002Fe' \\> 8\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction \\\u003C 50 %\n* Significant valve disease (Grade III or higher)\n* History of interventional or surgical valve repair\n* Regional wall motion abnormalities\n* Respiratory diseases as a known cause for dyspnea\n* Atrial flutter or fibrillation during examination\n* Hypertrophic\u002Frestrictive\u002Farrhythmogenic\u002Fdilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy\n* History of heart transplantation",{"count":135,"type":23},150,"Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.",[138,28],"Heart Failure With Preserved Ejection Fraction","2024-05-08",{"date":141,"type":35},"2024-05-09",{"date":143,"type":35},"2024-02-23",{"date":145,"type":23},"2028-01",{"name":147,"class":42},"University Medical Center Goettingen",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":43},"100472747","assessment-and-digital-health-based-intervention-on-subclinical-organ-damage-and-cardiovascular-risk-in-chinese-100472747","NCT05435898","Assessment and Digital-health Based Intervention on Subclinical Organ Damage and Cardiovascular Risk in Chinese","Comprehensive Assessment and Digital-health Based Intervention on Early-stage Cardiovascular Organ Damage and Cardiovascular Risk in Chinese: An All-comer Registry Study","Inclusion Criteria:\n\n* aged 18 years or older\n* willing to participate the study and sign informed consent\n* available for long-term follow-up\n\nExclusion Criteria:\n\n* severe heart disease (NYHA IV)\n* stage 4 or 5 CKD\n* malignant tumors or with life expectancy less than 5 years\n* stroke within 3 months\n* refuse to participate the study or not available for long-term follow up",{"count":156,"type":23},4000,"To comprehensively evaluate subclinical organ damage of Chinese adults and its association with future cardiovascular disease and events.\n\nTo observe the significance of intervention based on digital health in preventing the onset and\u002For progression of subclinical organ damage and cardiovascular disease and events.",[81,28,159,160],"Subclinical Organ Damage","Digital Health",[162,163,164,165,166,167],"Coronary Heart Disease","Arterial stiffness","Left ventricular hypertrophy","Left ventricular diastolic dysfunction","Intima-media thickness","Cardiovascular events","NOT_YET_RECRUITING","2022-06-23",{"date":171,"type":35},"2022-06-28",{"date":173,"type":23},"2022-10-01",{"date":175,"type":23},"2029-09-30",{"name":177,"class":42},"Shanghai 10th People's Hospital"]